Osaic Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

Osaic Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,157	Closed	-$1.86M	–	7542
2021 Q2	$1.86M	Sell	10,157 -1,673	-14%	-$287K	﹤0.01%	1791
2021 Q1	$1.81M	Sell	11,830 -15,001	-56%	-$2.32M	﹤0.01%	1712
2020 Q4	$4.19M	Sell	26,831 -1,379	-5%	-$177K	0.01%	948
2020 Q3	$3.23M	Buy	28,210 +601	+2%	+$64.8K	0.01%	1012
2020 Q2	$3.09M	Buy	27,609 +4,064	+17%	+$431K	0.01%	974
2020 Q1	$1.95M	Buy	+23,545	New	+$2.31M	0.01%	1087

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Osaic Holdings's ALXN Position: Q3 2021 in Review

Osaic Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 10,157 shares — an estimated $1.86M sold.

Osaic Holdings first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $4.19M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Osaic Holdings reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Osaic Holdings sold 10,157 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.86M.
Osaic Holdings first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Osaic Holdings's Alexion Pharmaceuticals position peaked at $4.19M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Osaic Holdings's 13F filing for Q3 2021, filed 5 Nov 2021.